Israeli Doctor Revolutionizes Treatment for Metatarsus Adductus (MTA) in Newborns, Replacing The Need For Casting And Surgical InterventionTEL AVIV, Israel, Jan. 16, 2024 /PRNewswire/ -- UNFO Med Ltd., the manufacturer of the Universal Neonatal Foot Orthotics (UNFO) system, is thrilled to introduce a first of its kind corrective foot brace for the treatment of various foot conditions such as Metatarsus Adductus (MTA), a common condition in newborns that causes the front half of the foot, or forefoot, to turn inward.

以色列医生彻底改变了新生儿跖骨内收肌（MTA）的治疗方法，取代了铸造和手术干预的需要以色列特拉维夫，2024年1月16日/PRNewswire/--UNFO Med Ltd.，通用新生儿足部矫形器（UNFO）系统的制造商，很高兴能推出第一款矫正足托，用于治疗各种足部疾病，如跖骨内收（MTA），这是新生儿常见的疾病，会导致脚的前半部分或前脚向内。

Other conditions include Metatarsus Varus, forefoot adduction, intoeing, and skew foot. This development marks a significant milestone in pediatric orthopedic care, replacing the need for casting and surgical intervention..

其他情况包括跖骨内翻，前脚内收，内翻和脚偏斜。这一发展标志着儿科骨科护理的一个重要里程碑，取代了铸造和手术干预的需要。。

Continue Reading

继续阅读

The Universal Neonatal Foot Orthotic (UNFO) brace is the first short foot orthotic device that is worn below the ankle and used for the treatment of metatarsus adductus (MTA) and other foot conditions in infants. Photo credit: OCO renders

通用新生儿足部矫形器（UNFO）支具是第一个短脚矫形器，佩戴在脚踝以下，用于治疗婴儿的跖骨内收（MTA）和其他足部疾病。图片来源：OCO渲染

Metatarsus Adductus – also known as MTA – is a congenital foot condition that occurs in approximately 7% of births. When one sibling has this genetic anomaly, the chances of the next child being born with the condition increases to 12%. This condition causes the front half of the foot to turn inward due to an off-center deviation at the tarsometatarsal joints (the midfoot, or middle part of the foot).

跖骨内收肌（也称为MTA）是一种先天性足部疾病，约占新生儿的7%。当一个兄弟姐妹患有这种遗传异常时，下一个孩子出生时患有这种疾病的机会增加到12%。由于跗跖关节（中足或脚的中间部分）偏离中心，这种情况会导致脚的前半部分向内转动。

If left untreated, the child may be at increased risk for foot deformities, foot pain and problems with their gait, causing the child to frequently fall..

如果不及时治疗，孩子可能会增加足部畸形、足部疼痛和步态问题的风险，导致孩子经常摔倒。。

Traditionally, casting and surgical intervention have been the standard for addressing MTA in infants. Casting can be extremely uncomfortable and painful for the child, causing stress for both the infant and the parents. However, UNFO's innovative corrective foot brace, developed under the guidance of Israeli, Dr.

传统上，铸造和手术干预一直是解决婴儿MTA的标准。铸造对孩子来说可能非常不舒服和痛苦，给婴儿和父母带来压力。然而，UNFO在以色列Dr。

Izak Daizade, eliminates the necessity for casting and surgery, providing a non-invasive and highly effective alternative for parents and their newborns..

Izak Daizade，消除了铸造和手术的必要性，为父母及其新生儿提供了一种非侵入性和高效的替代方案。。

After dedicating over thirty years to the care of newborns, Dr. Izak Daizade, Founder and R&D Director, UNFO Med Ltd, identified a critical gap in the treatment of MTA. Following seven years of dedicated research, he unveiled UNFO, a short foot orthotic device worn below the ankle. Engineered with precision to address the three-dimensional anatomic deformities and misalignments in infants' foot structures, UNFO represents the first of its kind in pediatric orthopedics.

UNFO Med Ltd创始人兼研发总监伊扎克·戴扎德（Izak Daizade）博士在致力于新生儿护理三十多年后，发现MTA治疗方面存在重大差距。经过七年的专注研究，他推出了UNFO，一种短脚矫形器，佩戴在脚踝以下。UNFO经过精确设计，可解决婴儿足部结构的三维解剖畸形和错位问题，是儿科骨科领域的首创。

Its discreet, sandal-like design not only ensures proper correction but also delivers gentle and comfortable care for the tiniest patients. Dr. Daizade has treated over 15,000 patients with the UNFO brace and has had a 95% rate of success[1].'As a pediatric orthopedic specialist, my goal has always been to provide the best possible care for newborns facing challenges such as Metatarsus Adductus,' said Dr.

其谨慎的凉鞋式设计不仅可以确保正确的矫正，还可以为最小的患者提供温和舒适的护理。Daizade博士用UNFO支具治疗了15000多名患者，成功率为95%[1]作为一名儿科骨科专家，我的目标一直是为面临诸如跖骨内收肌等挑战的新生儿提供尽可能最好的护理。

Izak Daizade, CEO of UNFO Med Ltd. 'UNFO's corrective foot brace represents a significant advancement in our approach to pediatric orthopedics. This non-invasive solution not only transforms the treatment of newborns born with MTA, but also signifies a new era of proactive and compassionate care. I am excited about the positive impact this innovation will have on the lives of infants and their families across the U.S.'Dr.

UNFO医疗有限公司首席执行官伊扎克·戴扎德（IzakDaizade）表示，UNFO的矫正脚支架代表了我们儿科骨科方法的重大进步。这种非侵入性的解决方案不仅改变了MTA新生儿的治疗方式，而且标志着一个积极和富有同情心的护理新时代。我很高兴这项创新将对美国各地婴儿及其家人的生活产生积极影响。

John Herzenberg, a world-renowned Clinical Professor of Orthopedic Surgery, former Director of Pediatric Orthopedics at Sinai Hospital, and the Founder and Director of the International Center for Limb Lengthening at the hospital's Rubin Institute for Advanced Orthopedics. He has been listed in U.S.

约翰·赫森伯格（JohnHerzenberg），世界著名的骨科临床教授，西奈医院儿科骨科前主任，医院鲁宾高级骨科研究所国际肢体延长中心创始人兼主任。他已在美国上市。

News Top Doctors, as being in the top 1% of his field. Before his recent retirement, he used UNFO to treat over thirty patients. According to him, 'The brace is well-tolerated, and in the ma.

新闻是顶级医生，在他的领域中排名前1%。在他最近退休之前，他使用UNFO治疗了30多名患者。据他说，“支具的耐受性很好，在ma中。